alexa TGF-β Receptor I Kinase Inhibitor Combinatorial Treatment With Radiation Inhibits Tumor Growth And Metastasis In Syngeneic Breast Mouse Models
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

Global Summit on Oncology & Cancer
May 25-27, 2017 Osaka, Japan

Yhun Y Sheen, Ji Y Park and Ji W Choe
College of Pharmacy- Ewha Womans University, Korea
Posters & Accepted Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956-C1-100
EW-7197, TGF-β receptor I kinase inhibitor combinatorial treatment with radiation inhibits tumor growth and metastasis in syngeneic breast mouse models. Radio-resistance and relapse after chemotherapy is a life-threatening problem for breast cancer patients. We identified the molecular signatures of the recurrent breast cancer patients after radiotherapy, which showed the upregulation of TGF-β signaling and the epithelial-to-mesenchymal transition (EMT). In order to find the potential therapeutic strategies to improve radiation therapy, we conducted gene set enrichment analysis, a computational method that determines whether an a priori defined gene set shows statistically significant between two phenotypes, using the breast cancer clinical data with Servant cohort (GSE30682). Since, we have proved that EW-7197 showed the inhibitory effect in vivo in various breast cancer mouse models previously. We carried out experiments that might test if combinatorial treatment of EW-7197 improves radiation therapy using two syngeneic mouse models. Met 1 cells, which are derived from primary tumors of the FVB/N transgenic mouse with mammary tumor-polyoma virus middle T antigen (MMTV-PyVmt), were injected to fourth inguinal fat pads of FVB/N mice. 4T1 cells, which are derived from primary tumors of Balb/c mice, were injected as same way into Balb/c mice. Mice were treated with the fractionatedradiation (total dose 12 Gy, 4 Gy X3) with or without the combinatorial treatment of EW-7197 (2.5 mg/kg). Combinatorial treatment of EW-7197 synergistically reduced the primary tumor size when combined with radiation and inhibits lung metastasis efficiently. This effect of EW-7197 maybe related to the breast cancer stem-like phenotype, which is increased by 4Gy irradiation in vitro. We need to further study to conclude the therapeutic mechanisms of EW-7197 on improving radiation therapy.

Yhun Sheen has her research interest in developing new anti-cancer drug. She had participated in the development of TEW-7197 which is currently under clinical trial in USA (NCT02160106).

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version